No. A blood test cannot diagnose Alzheimer’s disease by itself. The FDA-cleared Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio can help determine whether a person with cognitive symptoms is likely to have amyloid pathology associated with Alzheimer’s, but the FDA explicitly states that a positive result “does not establish a diagnosis.” Diagnosis still requires a clinical assessment and, in some cases, additional testing. Consider a 68-year-old who has begun repeating questions and struggling to manage bills.
A positive blood result could strengthen the case for further Alzheimer’s evaluation, while a negative result could direct the clinician toward other explanations, such as medication effects, depression, sleep apnea, thyroid disease, vitamin deficiency, vascular injury or another neurological disorder. Neither result, standing alone, identifies the cause of the person’s difficulties. The test represents a meaningful change because drawing blood is generally less invasive and more accessible than collecting cerebrospinal fluid through a lumbar puncture, and potentially less costly and burdensome than amyloid PET imaging. That convenience does not make it a screening test for anyone worried about occasional forgetfulness. Its FDA-cleared use is limited to a defined group of symptomatic adults evaluated in specialized care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Can the FDA-Cleared Blood Test Diagnose Alzheimer’s Disease?
- Who Is the Alzheimer’s Blood Test Intended For?
- What Positive, Negative and Indeterminate Results Mean
- How Clinicians May Use the Test in a Dementia Evaluation
- Validation Results and Important Study Limitations
- False Results Can Affect Care and Emotional Well-Being
- Questions to Ask Before and After Testing
- Frequently Asked Questions
Can the FDA-Cleared Blood Test Diagnose Alzheimer’s Disease?
The test was cleared by the fda on May 16, 2025. Its full name is the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, manufactured by Fujirebio Diagnostics. It is a prescription Class II in-vitro diagnostic that received 510(k) clearance through the FDA’s substantial-equivalence pathway. That regulatory route is different from the drug-approval process, so describing the test as “FDA-approved” is inaccurate. ([FDA 510(k) database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K242706)) The laboratory test measures phosphorylated tau 217, or p-tau217, and beta-amyloid 1-42 in K2EDTA human plasma. It combines the two measurements into a ratio using the Lumipulse G1200 system.
The result helps a clinician assess whether amyloid pathology is likely, unlikely or unresolved. Amyloid plaques are a hallmark of Alzheimer’s disease, but detecting amyloid is not identical to diagnosing the clinical disease. ([FDA 510(k) Decision Summary K242706](https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242706.pdf)) That distinction matters in practice. A patient may have amyloid changes alongside vascular brain injury, Lewy body disease or another contributor to cognitive impairment. Conversely, a patient’s memory problems may be caused by something unrelated to amyloid. The blood test supplies one biological clue; it does not replace the medical history, cognitive evaluation, neurological examination or assessment of daily functioning.
Who Is the Alzheimer’s Blood Test Intended For?
The FDA-cleared indication covers adults age 50 and older who have signs and symptoms of cognitive decline and are being evaluated in a specialized care setting. It is available by prescription, not as an at-home wellness test or a population-wide screening test. Although the FDA’s May 2025 press release described the population as age 55 and older, the legally operative clearance document and indications for use specify age 50 and older. ([FDA clearance document](https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242706.pdf); [FDA press release](https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease)) A suitable patient might be a 73-year-old referred to a memory clinic after a year of worsening word-finding difficulty, missed appointments and confusion while driving familiar routes.
The test could contribute useful evidence after the clinician has reviewed symptom progression, medications, mood, sleep, medical conditions and cognitive-test results. The cleared indication does not extend to a healthy 45-year-old who wants to estimate future Alzheimer’s risk, or to an asymptomatic 65-year-old seeking reassurance because a parent had dementia. Using the test outside the studied population may produce a result whose meaning is less certain. Testing people with a low likelihood of disease also increases the practical danger that a positive result will mislead rather than clarify.
What Positive, Negative and Indeterminate Results Mean
A ratio of 0.00738 or higher is classified as positive and is consistent with amyloid pathology being likely. This finding may support further evaluation for Alzheimer’s disease, but it cannot establish that the patient has Alzheimer’s or any other cognitive disorder. A positive result also cannot show how quickly symptoms will progress, how much amyloid is in the brain or whether amyloid is the only cause of impairment. ([FDA 510(k) Decision Summary K242706](https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242706.pdf)) A ratio of 0.00370 or lower is classified as negative and is consistent with amyloid pathology being unlikely. That result should prompt investigation of other causes of cognitive decline.
For example, if a 62-year-old with slowed thinking receives a negative result, the clinician might give greater attention to sedating medications, severe sleep apnea, depression, prior strokes or metabolic abnormalities. A negative result does not prove that the person is cognitively healthy. Ratios from 0.00371 through 0.00737 are indeterminate. This is not a mildly positive or mildly negative diagnosis; it means the blood result does not resolve amyloid status. The clinician may consider amyloid PET imaging, cerebrospinal-fluid testing or other evaluation based on the patient’s symptoms and treatment decisions.
How Clinicians May Use the Test in a Dementia Evaluation
A dementia evaluation usually begins with the pattern and timing of symptoms. Clinicians ask whether changes are gradual or sudden, which cognitive abilities are affected, and whether the person can still manage medications, finances, cooking and transportation. Cognitive testing, a neurological examination, laboratory work and structural brain imaging may follow. The amyloid blood test fits within this process rather than replacing it. Compared with amyloid PET imaging, a blood draw is easier to perform and does not require a specialized scanner or radioactive tracer.
Compared with cerebrospinal-fluid analysis, it avoids a lumbar puncture. The tradeoff is that an indeterminate blood result—or a result that conflicts with the clinical picture—may still lead to one of those confirmatory procedures. Suppose a symptomatic patient has a positive blood result and is being considered for a treatment that requires evidence of amyloid pathology. The clinician must interpret the result under the treatment’s eligibility requirements, discuss uncertainties and decide whether confirmatory PET or cerebrospinal-fluid evidence is appropriate. A laboratory number should not trigger treatment without attention to diagnosis, disease stage, other health conditions and potential adverse effects.
Validation Results and Important Study Limitations
In the FDA-reviewed study, 499 cognitively impaired patients received the blood test and a reference assessment using amyloid PET imaging or cerebrospinal fluid. Among 219 positive blood-test results, 201 were amyloid-positive by the reference method. That produced a positive predictive value of 91.8%, with a 95% confidence interval of 87.8% to 94.6%. Among 182 negative results, five were amyloid-positive, meaning 97.3% of negative results matched a negative PET or cerebrospinal-fluid result. These numbers should not be relabeled as general “accuracy,” sensitivity or specificity. ([FDA 510(k) Decision Summary K242706](https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242706.pdf)) Indeterminate results were not rare.
Ninety-eight of the 499 participants—19.6%—fell into the unresolved range. Exactly half of those 98 participants were amyloid-positive by PET or cerebrospinal-fluid testing. In a clinic evaluating 100 patients with a similar profile, that proportion would translate to roughly 20 people whose blood results could not settle the amyloid question. The study population also limits how broadly its findings can be applied. Participants ranged from 52 to 93 years old; 58.1% had Alzheimer’s disease, 30.9% had mild cognitive impairment and 9.8% had subjective cognitive decline. The cohort was 84.8% White and included no patients with other neurological diseases. Performance in general primary care, more diverse populations, asymptomatic adults or people with competing neurological conditions cannot be assumed to match these results.
False Results Can Affect Care and Emotional Well-Being
The FDA identifies false-positive and false-negative results as the test’s principal risks. A false positive could contribute to an inappropriate diagnosis or treatment, emotional distress, unnecessary expense, treatment side effects and delay in finding the actual cause of cognitive decline.
A false negative could delay effective treatment and lead to additional testing. ([FDA press release](https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease)) For example, a positive result in someone whose impairment is primarily caused by another condition could draw attention away from a treatable contributor. Families should avoid making irreversible decisions about employment, driving, housing or finances from the blood result alone, especially before a clinician has completed the broader evaluation.
Questions to Ask Before and After Testing
Before testing, patients and care partners can ask whether the person meets the cleared indication, how the result would change the evaluation, and whether insurance coverage or additional testing may be needed. They can also ask who will explain an indeterminate result and whether PET imaging or a lumbar puncture would be considered if the blood finding conflicts with the symptoms. After the result, useful questions include: “Does this finding match the clinical picture?”, “What other causes are still being investigated?” and “Would confirmatory testing alter treatment?” A patient with a ratio of 0.00500, for example, falls within the FDA-defined indeterminate interval of 0.00371 to 0.00737 and should not be told that the result establishes or excludes Alzheimer’s disease.
Frequently Asked Questions
Is the Alzheimer’s blood test FDA-approved?
No. The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio is FDA-cleared through the 510(k) pathway. “FDA-cleared” is the accurate regulatory description.
Can a positive blood test confirm Alzheimer’s disease?
No. A positive result is consistent with likely amyloid pathology, but the FDA states that it does not establish a diagnosis of Alzheimer’s disease or another cognitive disorder.
Can someone without memory symptoms take the test for screening?
That is not its FDA-cleared use. The indication is for adults age 50 and older who have signs and symptoms of cognitive decline and are being evaluated in specialized care.
Does a negative result rule out every cause of dementia?
No. It indicates that amyloid pathology is unlikely. The patient may still have cognitive impairment from another neurological, psychiatric, sleep-related, medication-related, vascular or metabolic cause.
What happens after an indeterminate result?
The clinician may consider further evaluation, including amyloid PET imaging or cerebrospinal-fluid testing. In the FDA-reviewed study, 19.6% of results were indeterminate.
